These findings point towards a higher benefit of Cetuximab treatment for RM-HNSCC patients with higher expression levels of ITGB4, as surrogate for enhanced EGFR-mediated EMT. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.